Last reviewed · How we verify
CHS-1420
CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity.
CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | CHS-1420 |
|---|---|
| Sponsor | Coherus Oncology, Inc. |
| Drug class | Bispecific antibody |
| Target | CD47 and CD40 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking the CD47 'don't eat me' signal on cancer cells while activating CD40 on dendritic cells and macrophages, CHS-1420 promotes both innate immune activation and adaptive T-cell responses against tumors. This dual engagement aims to overcome tumor immune evasion and drive durable anti-cancer immunity.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Cytokine release syndrome
- Infusion-related reactions
- Anemia
- Fatigue
Key clinical trials
- A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions (PHASE1)
- Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHS-1420 CI brief — competitive landscape report
- CHS-1420 updates RSS · CI watch RSS
- Coherus Oncology, Inc. portfolio CI